Locations:
Search
Cleveland Clinic Innovations portfolio company Centerline Biomedical’s Intra-Operative Positioning System (IOPS) aims to help clinicians visualize endovascular tools in real-time and reduce their dependence on fluoroscopy systems.
Bernardo Perez-Villa, MD, MSc, Senior Engagement Partner, Innovations, shares with Cardiac Care three promising technologies poised to reshape how we address cardiovascular diseases. Cleveland Clinic Innovations portfolio companies Advanced NanoTherapies Inc., Cardionomic Inc., and Mitria Medical, are featured.
510(k) clearance by FDA further addresses the market need to reduce physician exposure to harmful x-ray radiation during image-guided, endovascular procedures.
Investment will allow NeuroTherapia to continue the development of an orally available treatment for Alzheimer's disease. Joseph Rich, JD, MBA, Senior Director, Governance, Grants, and Policies, Cleveland Clinic Innovations, comments.
In the Cleveland Clinic Innovations profile series, members of the Innovations team share their journey to joining the Innovations department at Cleveland Clinic, what they find inspiring about their role and what innovation means to them.
Cleveland Clinic inventor Glenn Werneburg, MD, PhD, shares his research and its influence on patient care as part of Cleveland Clinic Innovations’ Inventor Chronicle series.
Hunter Rogers of Cleveland Clinic Innovations has been recognized as one of 2024’s 42 rising stars under 40 who are leaders in healthcare.
In the Nurse Inventor Spotlight series, Cleveland Clinic nurses who have embarked on the innovation journey share what they find inspiring about their role, how they identified an unmet need and how their solution could impact both patients and caregivers, their experience with Innovations, and what innovation means to them.
Cleveland Clinic has introduced the Cleveland Clinic Cognitive Battery (C3B), an innovative tool, technology developed by Cleveland Clinic and licensed to Cleveland Clinic Innovations portfolio company, Qr8 Health. It has shown promising results during its rollout, outperforming traditional screening methods. Zach Eisen, Principal, Ventures, Digital Health & Medical Devices shares his insight on the advancements made.
